Flagship’s AI Company Generate Inks Deal Worth up to $1B With Novartis

Flagship Pioneering–backed Generate:Biomedicines has signed its second major Big Pharma partnership, bringing in $65 million upfront to use its AI platform to discover novel protein drug candidates.